This is a cash and stock transaction that values Penumbra at $374 per share. The move helps Boston Scientific expand its vascular and neurovascular portfolios, gaining new treatments for pulmonary embolism, stroke, deep vein thrombosis and many other critical cardiovascular conditions. This is a cash and stock transaction that values Penumbra at $374 per share. The move helps Boston Scientific expand its vascular and neurovascular portfolios, gaining new treatments for pulmonary embolism, stroke, deep vein thrombosis and many other critical cardiovascular conditions. | | |
|
CMS has made it a priority to increase payments for procedures performed by office-based labs and ambulatory surgical centers. This was reflected in policy changes made as part of the 2026 Medicare Physicians Fee Schedule. CMS has made it a priority to increase payments for procedures performed by office-based labs and ambulatory surgical centers. This was reflected in policy changes made as part of the 2026 Medicare Physicians Fee Schedule. | | |
|
It was another strong quarter for Edwards Lifesciences as the company's TAVR platform continues to gain momentum. The FDA's approval of multiple Edwards valves for the treatment of asymptomatic severe AS represents a potential game-changer for the entire industry. It was another strong quarter for Edwards Lifesciences as the company's TAVR platform continues to gain momentum. The FDA's approval of multiple Edwards valves for the treatment of asymptomatic severe AS represents a potential game-changer for the entire industry. | | |
|
Medtronic has held a minority investment in CathWorks for several years, and the two organizations entered into a co-promotion agreement in 2022. Once finalized, the move will increase Medtronic's presence in the cath lab. Medtronic has held a minority investment in CathWorks for several years, and the two organizations entered into a co-promotion agreement in 2022. Once finalized, the move will increase Medtronic's presence in the cath lab. | | |
|
The company's implantable Barostim device continues to make an impact on patient care. CVRx also shared excitement about the year ahead, pointing to an important new clinical trial. The company's implantable Barostim device continues to make an impact on patient care. CVRx also shared excitement about the year ahead, pointing to an important new clinical trial. | | |
|
Mandates for universal ECG screening are gaining momentum as a way to combat the risk of SCA. However, the ACC warned, modern healthcare systems were not built to withstand such a rise in demand. These mandates will also result in higher costs and other unintended consequences. Mandates for universal ECG screening are gaining momentum as a way to combat the risk of SCA. However, the ACC warned, modern healthcare systems were not built to withstand such a rise in demand. These mandates will also result in higher costs and other unintended consequences. | | |
|
Anteris Technologies is known for its biomimetic transcatheter heart valve, the DurAVR THV System. The device is the first of its kind and has gained considerable attention as the TAVR market continues to grow. Anteris Technologies is known for its biomimetic transcatheter heart valve, the DurAVR THV System. The device is the first of its kind and has gained considerable attention as the TAVR market continues to grow. | | |
|
Abbott pointed to double-digit growth for its Navitor TAVR valve as well as big gains for the TriClip and MitraClip devices. The company also shared positive sales figures for its EP, heart failure and rhythm management portfolios. Abbott pointed to double-digit growth for its Navitor TAVR valve as well as big gains for the TriClip and MitraClip devices. The company also shared positive sales figures for its EP, heart failure and rhythm management portfolios. | | |
|
Johnson & Johnson reported $24.6 billion in sales for the fourth quarter of 2025, up 9.1% from the previous year. On an earnings call with investors, the company's CEO sang the praises of the company's cardiovascular health division. Johnson & Johnson reported $24.6 billion in sales for the fourth quarter of 2025, up 9.1% from the previous year. On an earnings call with investors, the company's CEO sang the praises of the company's cardiovascular health division. | | |
|
Neil G. Bluhm, a billionaire philanthropist with deep ties to Chicago, has donated an additional $50 million to a high-volume facility that already bears his name. Neil G. Bluhm, a billionaire philanthropist with deep ties to Chicago, has donated an additional $50 million to a high-volume facility that already bears his name. | | |
|
